Etrolizumab

From WikiMD's Wellnesspedia

Etrolizumab is a monoclonal antibody designed for the treatment of Ulcerative colitis and Crohn's disease. It is developed by Genentech, a member of the Roche Group.

Mechanism of Action[edit | edit source]

Etrolizumab is a humanized monoclonal antibody that selectively binds to the beta7 subunit of the integrin heterodimer. This binding inhibits the interaction of the beta7 subunit with MAdCAM-1 and E-cadherin, thereby preventing the migration of leukocytes into gut tissues.

Clinical Trials[edit | edit source]

Etrolizumab has been studied in Phase III clinical trials for the treatment of moderate to severe ulcerative colitis and Crohn's disease. The results of these trials are pending.

Side Effects[edit | edit source]

The most common side effects of etrolizumab include nausea, headache, fatigue, and abdominal pain. Serious side effects can include infections, infusion reactions, and liver problems.

See Also[edit | edit source]


Etrolizumab Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD